<DOC>
	<DOCNO>NCT02749383</DOCNO>
	<brief_summary>This study Phase II , single center , randomize , double-blind , placebo-controlled study male female subject , age ≥ 19 year mild moderate seborrheic dermatitis face . All subject receive BID topical application PAC-14028 cream vehicle 4 week .</brief_summary>
	<brief_title>A Study Evaluate Safety Efficacy PAC-14028 Cream Seborrheic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Seborrheic</mesh_term>
	<criteria>Male female patient age 19 65 year old Clinical diagnosis seborrheic dermatitis facial area Erythema severity ≥ 2 Scaling severity ≥ 2 IGE ( Investigator 's Global Evaluation ) Score 2 3 Patients psoriasis , atopic dermatitis , facial acne , rosacea perioral dermatitis Patients infected bacteria , fungi , virus animal infectious disease facial area Patients administer topical antifungal agent , steroid , retinoids , calcineurin suppressant treatment seborrheic dermatitis within last 2 week Patients administer systemic antifungal agent , steroid , retinoids , immunosuppressant treatment seborrheic dermatitis within last 4 week Patients administer local antibiotic treatment seborrheic dermatitis within last 4 week Pregnant woman , breastfeed woman woman childbearing potential woman plan pregnancy study</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>